Skip to main content
. 2022 Feb 19;23:36. doi: 10.1186/s12931-022-01952-8

Table 3.

Changes in OCS use (dosage expressed as prednisone-equivalent) during treatment with benralizumab

Variable Evaluable N = 44 Starting dose ≤ 5 mg/die (N = 14) Starting dose > 5 mg/die (N = 30)
Any reduction 22 (50%) 8 (57.1%) 14 (46.7%)
Reduction from baseline
 100% 19 (43.2%) 6 (42.9%) 13 (43.3%)
 ≥ 90% 19 (43.2%) 6 (42.9%) 13 (43.3%)
 ≥ 75% 20 (45.5%) 6 (42.9%) 14 (46.7%)
 ≥ 25% 21 (47.7%) 7 (50%) 14 (46.7%)
No reduction 22 (50%) 6 (42.9%) 16 (53.3%)

Data are expressed as frequencies (N [%])